Form 4: Catalyst Pharmaceuticals Director Molly Harper Reports Stock Unit Vesting

Director Molly Harper reports vesting of restricted stock units in Catalyst Pharmaceuticals, resulting in the acquisition of 1,333 shares.

Summary

• On December 27, 2024, Molly Harper, a director of Catalyst Pharmaceuticals, Inc., reported the vesting of restricted stock units.
• This transaction resulted in the acquisition of 1,333 shares of common stock.
• Following the transaction, Harper directly owns 2,746 shares of common stock.
• Harper also directly owns 131,274 derivative securities in the form of restricted stock units.
• The restricted stock units vest in three equal tranches annually on December 27, 2023, 2024, and 2025.
• Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting.

Sentiment

Score: 5

Explanation: This is a neutral event, reflecting a standard vesting of stock units. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Stakeholder Impact

• The vesting of restricted stock units may have a minor dilutive effect on existing shareholders.

Key Dates